申请人:Zora Biosciences OY
公开号:EP2508895A1
公开(公告)日:2012-10-10
The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid-lipid concentration ratios of a biological sample and comparing them to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity.
本发明特别提供了一种方法及其用途,通过检测生物样本的脂质浓度或脂质-脂质浓度比,并将其与对照组进行比较,预测他汀类药物诱发的肌肉毒性或其并发症,如肌痛、肌病和横纹肌溶解症。与目前使用的临床标记物相比,该方法发现的脂质标记物在检测他汀类药物引起的肌肉毒性方面更具特异性和敏感性。本发明还提供了一种针对上述脂质的抗体,及其用于预测、诊断他汀类药物诱发的肌肉毒性。本发明还涉及包含脂质和/或其抗体的试剂盒,用于预测和/或诊断他汀类药物诱发的肌肉毒性。